Additional radiation effect on cell viability using neutron irradiated Cisplatin and Carboplatin: preliminary results

Alexandre Soares Leal; Juliana B Silva; Ana Olivia G Morais; Brigida Gomes de Almeida Schirmer

doi:10.15392/2319-0612.2025.2614

Authors

Alexandre Soares Leal Centro de Desenvolvimento de Tecnologia Nuclear – CDTN/CNEN. CTDN
Juliana B Silva Centro de Desenvolvimento da Tecnologia Nuclear (CDTN), Av. Antônio Carlos 6.627, Campus da UFMG, Pampulha, 31270-901, Belo Horizonte, Minas Gerais, Brazil.
Ana Olivia G Morais Centro de Desenvolvimento da Tecnologia Nuclear (CDTN), Av. Antônio Carlos 6.627, Campus da UFMG, Pampulha, 31270-901, Belo Horizonte, Minas Gerais, Brazil.
Brigida G A Schirmer Centro de Desenvolvimento da Tecnologia Nuclear (CDTN), Av. Antônio Carlos 6.627, Campus da UFMG, Pampulha, 31270-901, Belo Horizonte, Minas Gerais, Brazil.

DOI:

https://doi.org/10.15392/2319-0612.2025.2614

Keywords:

Cisplatin, carboplatin, radiochemotherapy, antitumoral effects

Abstract

The objective of this work was to investigate the effect on cell viability of radiolabeled complexes of cisplatin and carboplatin in cancer cells of the 4T1 and MDA-MB-231 lines from mice with mammary carcinoma. The complexes were labeled in the CDTN's TRIGA Mark I nuclear research reactor after 3 hours of irradiation. The analyzes were carried out after decay times of 1h and 24h. The results showed a more effective action of cisplatin compared to carboplatin in both cell lines and greater resistance in MDA-MB-231 cells. The additional effect of radiation was more evident in conditions of low resistance. Increasing the final activity of labeled compounds can amplify this effect. Investigations in this regard are underway.

Downloads

Download data is not yet available.

References

[1] DIAS, G.H.M. Cisplatina e Análogos: Drogas Inorgânicas Anticanceríginas. Química Nova vol. 12, p. 57-59, 1989.

[2] SIDDIK, Z.H., JONNES, M., BOXALL, F.E., HARRAP, K.E., Comparative distribution and excretion of cisplatin and carboplatin in mice. Cancer Chemother Pharmacol vol. 21, p.19-24, 1988. DOI: https://doi.org/10.1007/BF00262732

[3] AREBERG, J. Studies of radioactive cisplatin (Pt) for tumor imaging and therapy. PhD Thesis. Lund University, Malmo/Sweden, 2000.

[4] SOARES, M.A., MATTOS, J.L., PUJATTI, P.B, LEAL, A.S., SANTOS, W.G., SANTOS, R.G. Evaluation of the synergetic radiochemotherapy effects of the radio labelled cisplatin for the treatment of glioma. J Radioana Nucl Chem. vol. 292, p. 61-65,2011. DOI: https://doi.org/10.1007/s10967-011-1414-2

[5] NEWMAN, M.S., COLBERN, G.T., WORKING, P.K., Comparative pharmacokinetics, tissue distribution and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor bearing mice. Cancer Chemother Pharmacol, vol. 43, p. 1-7, 1999. DOI: https://doi.org/10.1007/s002800050855

[6] AREBERG, J., BJORKMAN, S., EINARSSON, L., FRANKENBERG, B., LUNDQVIST, H., MATTSSON, S., SORRGREN, K., SCHEIKE, O., WALLI, R. Gamma camera imaging of platinum in tumors and tissues of patients after administration of *™Pt-cisplatin. Acta Oncologica, vol. 38, p.221-228, 1999. DOI: https://doi.org/10.1080/028418699431654

[7] CORNELISSEN, B., VALLIS, K.A. Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy. Curr Drug Discov Technol, vol. 7, p. 263-279, 2010. DOI: https://doi.org/10.2174/157016310793360657

[8] KAWAI, K., MAKI, H., EHRLICH, W. Synthesis of 195mPt Radiolabeled, cis—dichlorodiammineplatinum (II) of High Chemical and Radiochemical Purity Using High Performance Liquid Chromatography. J Radioanal Nucl Chem vol. 136, p. 67-74, 1989. DOI: https://doi.org/10.1007/BF02165088

[9] LEAL, A.S., JUNIOR, A.D.C., ABRANTES, FM, MENEZES, M.A.B.C., FERRAZ, V., CRUZ, T.S., OLIVEIRA, M.C. Production of the radioactive antitumoral cisplatin. Appl Rad Isot vol. 64, p. 78-181, 2006. DOI: https://doi.org/10.1016/j.apradiso.2005.07.004

[10] LEAL, A.S., MARZANO, I.M., PEREIRA-MAIA, E.C., JACIMOVIC, R. Investigation of the potential antitumor radioactive complex of platinum (II) with tetracycline. J Radioanal Nucl Chem. vol. 309, p.85-89, 2016. DOI: https://doi.org/10.1007/s10967-016-4775-8

[11] LEAL, A.S., MENDES, B.M., BERNARDES, F.D. Estudo preliminar da dose absorvida e efetiva da cisplatina radiomarcada com 195mPt. Braz. J Rad. vol. 08-01, p.01-15, 2020. DOI: https://doi.org/10.15392/bjrs.v8i1.1147

[12] JAIN, A., DAS, T. Radiolabeled chemotherapeutics as a novel strategy for targeted cancer therapy: current insights and future perspectives. J Radioanal Nucl Chem vol. 333, p.1–15, 2024. DOI: https://doi.org/10.1007/s10967-023-09250-3

[13] BUCHEGGER, F., PERILLO-ADAMER, F., DUPERTUIS, Y.M., DELALOYE, A.B. Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging vol. 33, p. 1352-1363, 2006. DOI: https://doi.org/10.1007/s00259-006-0187-2

[14] REISSIG, F., RUNGE, R., NAUMANN, A., KOTZERKE, J. Cisplatin – A more efficient drug in combination with radionuclides? Nuklearmedizin vol. 61, pp 325-332, 2022. DOI: https://doi.org/10.1055/a-1759-1749

[15] CORNELISSEN, B., VALLIS, K.A. Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy, Curr Drug Discov Technol vol. 4, p. 263-279, 2010. DOI: https://doi.org/10.2174/157016310793360657

[16] BUSSOLOTTI, G.R., NIKEZIC, K.D., LEAL, A.S., ZIVKOVIC, M., MENDES, B.M. Computational Internal dosimetry of natural cisplatin activated in neutron flux: the 191Pt contribution. Braz. J Rad vol. 10-02A, p.01-17, 2022. DOI: https://doi.org/10.15392/bjrs.v10i2A.1816

[17] JÚNIOR, A.D.C., ABRANTES, F.M., MENEZES, M.A.B.C., LEAL, A.S., OLIVEIRA, M.C. Use of Labelled Cisplatin Obtained by Direct Irradiation in a Preliminary Biodistribution Study. Braz Arch Biol Technol vol.48, p. 85-88, 2005. DOI: https://doi.org/10.1590/S1516-89132005000700013

[18] KOMAROV E., WALLEN Q. Quality Control of Radiopharmaceuticals. Bulletin International Atomic Energy Agency (IAEA), vol 15-2, 1973.

[19] European Directorate for Quality of Medicines and Healthcare (EDQM) of the Councik of Europe. Available at: https://www.ema.europa.eu. Accessed on 10 Nov 2024.

[20] Quality Control in Production Radiopharmaceuticals. International Atomic Energy Agency (IAEA) TEC-DOC 1856, 2018

[21] GILLINGS, N., HJELSTUEN, O., BALLINGER, J. et al. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI radiopharm. chem. 6, 8, 2021. DOI: https://doi.org/10.1186/s41181-021-00123-2

[22] MOLAVIPORDANJANI S., HOSSEINIMEHR, S.J. Fundamental Concepts of Radiopharmaceuticals Quality Controls. Pharm Biomed Res vol.4(3), p.1-8, 2018. DOI: https://doi.org/10.18502/pbr.v4i3.538

[23] SOUZA, C.M., OLIVEIRA, G.C., CAMPOS, C.B., LOPES, M.T.P., FERREIRA, M.D., ANDRADE, SP. Carboplatin delays mammary cancer 4T1 growth in mice. Pathol. Res. Pract. vol. 209(1), p. 24-29, 2013. DOI: https://doi.org/10.1016/j.prp.2012.10.003

[24] GALLUZZI, L., et al. Molecular mechanisms of cisplatin resistance. Oncogene, vol. 31(15), p. 1869-1883, 2012. DOI: https://doi.org/10.1038/onc.2011.384

[25] Dasari, S, Tchounwou, PB. “Cisplatin in cancer therapy: molecular mechanisms of action”, Eur J Pharmacol. Vol. 740, pp. 364-378 (2014). DOI: https://doi.org/10.1016/j.ejphar.2014.07.025

[26] MARULLO, R. et al. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One, vol. 8(11), e81162, 2013. DOI: https://doi.org/10.1371/journal.pone.0081162

[27] YANG, X. et al. Functional consequences of BRCA1 missense variants, Cancers vol. 3(1), p. 75-88, 2011.

[28] GUIRO, K., PATEL, A.S., GRECO, S.J., RAMESHWAR, P., ARINZEH, T.L Investigating breast cancer cell behavior using tissue engineering scaffolds. PLoS One, vol. 10(4), e0118724, 2015. DOI: https://doi.org/10.1371/journal.pone.0118724